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Using long term mortality to 
determine which perioperative 
risk factors of mortality following 
hip and knee replacement may be 
causal
Linda P. Hunt1, Michael R. Whitehouse  1,2, Peter W. Howard3, Yoav Ben-Shlomo4 & 
Ashley W. Blom1,2
Observational studies have identified surgical factors that are associated with a reduced risk of 
mortality after joint replacement. It is not clear whether these are causal or reflect patient selection. 
Data on the first primary hip (n = 424,156) and knee replacements (n = 469,989) performed for 
osteoarthritis in the National Joint Registry were analysed. Flexible parametric survival modelling was 
used to determine if risk factors for mortality in the perioperative period persisted. To explore selection 
bias, standardised mortality ratios were calculated for all-cause, respiratory and smoking related cancer 
mortality using population rates. Selection was apparent for hip resurfacing, combined spinal and 
general anaesthetic and unicondylar knee implants; reduced mortality was observed for many years for 
both all and other causes of mortality with a waning effect. Mechanical thromboprophylaxis was also 
suggestive of selection although patients receiving aspirin had sustained reduced mortality, possibly 
due to to a cardioprotective effect. Posterior approach for hips was ambiguous with a possible causal 
component. Spinal anaesthesia was suggestive of a causal effect. We are reliant on observational data 
when it is not feasible to undertake randomised trials. Our approach of looking at long term mortality 
risks for perioperative interventions provides further insights to differentiate causal interventions from 
selection. We recommend the use of aspirin chemothromboprophylaxis, the posterior approach and 
spinal anaesthetic in total hip replacement due to the apparent causal effect on reduced mortality.
Total hip replacement (THR), total knee replacement (TKR) and unicompartmental knee replacement (UKR) 
cause short-term increases in mortality persisting for 90-days in hips1 and 45-days in knees2. Observational 
studies have identified surgical-related factors associated with decreased mortality. For hip replacement, these 
included posterior approach, thromboprophylaxis, spinal anaesthetic1 and resurfacing hip replacement3. For knee 
replacement, unicompartmental knee replacement was associated2,4.
Surgical-related exposures may be confounded by indication despite statistical adjustment. Randomised con-
trolled trials are the “gold standard” for inferring causality but are unfeasible when the primary outcome is rare. 
Patients undergoing joint replacement are pre-selected as fit enough to undergo surgery and hence are healthier 
than the general population. The overall mortality in this population is less than expected using general popu-
lation mortality rates, but over time this reduced risk diminishes5. Knowledge of the cause of death is helpful 
as health selection would be associated with reduced mortality from respiratory and smoking-related cancers, 
causes unlikely to be influenced by any perioperative surgery-related factor.
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Our aim was to determine whether “protective” factors previously identified may be due to selection by exam-
ining extended follow-up cause-specific linked mortality data. We hypothesised that (i) truly causal interventions 
which only influence the perioperative period would show an acute short-term reduction in mortality. However, 
conditional on survival to the end of this period, the subsequent mortality patterns should be the same for both 
exposed and unexposed groups. We defined the perioperative period as being 90 days as this is the timepoint at 
which we have previously shown the increased risk of perioperative mortality associated with the surgical inter-
vention returns to baseline1. (ii) If healthier participants were selected for the intervention, this group would have 
a persistently lower mortality at all time periods, that was unlikely to be explicable by the intervention, though 
over time mortality risks would converge towards that seen in the general population due to attenuation. (iii) 
There may be a causal benefit of the intervention but there is also selection of which patients receive this. In this 
case, it may not be possible to differentiate causality from selection.
Methods
Patients and Data Sources. 539,372 and 589,028 linkable primary THRs and TKRs in the National Joint 
Registry of England and Wales (NJR), undertaken April 2003 to December 2012 inclusive and reported in the 
10th Annual Report6 were analysed. Dates of death were obtained from NHS Personal Demographics Service on 
23rd February 2013. We excluded 261 THRs and 243 TKRs because the NHS number was untraceable, consent 
had been withdrawn or for ambiguous age or gender and a further 6,182 THRs (3,091 patients) and 15,142 TKRs 
(7,571 patients) with simultaneous bilateral operations. 479,191 THRs and 550,787 TKRs had osteoarthritis (OA) 
as the only indication for surgery; these two groups were analysed separately.
Patients often had other hip or knee procedures recorded, making it difficult to describe mortality associated 
with one incident procedure. Furthermore, when left and right joints were replaced at different times, any subse-
quent death would be included twice. After exploring several strategies, analysis was based on the first primary 
hip or knee procedure reported in the NJR; 424,156 first THRs and 469,989 first TKRs, of which 33,759 and 
36,003 respectively died on/before our censoring date (31st December 2012), as described previously7. For those 
who died, we obtained the main causes of death (ICD 10) from the Office for National Statistics (ONS) via NJR 
linkage to the patient’s Hospital Episode Statistics (HES) identifier, thereby excluding patients in the NJR with 
no inpatient HES records up to the end of November 2012. The latter included patients with no NHS-funded 
procedures recorded in the NJR, or with procedures performed only in Wales. 332,734 of the patients undergoing 
hip replacement (26,766 deaths) and 384,291 of the patients undergoing knee replacement (29,802 deaths) could 
be linked7.
Exposures. Surgical related interventions found to be important in our earlier short-term mortality publica-
tions: posterior surgical approach, thromboprophylaxis, spinal anaesthetic, resurfacing hip replacement (for hip 
replacement)1 and unicompartmental knee replacement2.
Other covariates. We also modelled age, gender, year of primary operation (2003–2005, 2006–2008, 
2009–2012) and ASA grade. Where available, each procedure was linked to the patient’s HES inpatient records 
over a 5-year period prior to the operation date which were used to compute area deprivation quintiles8–10 and 
Charlson co-morbidity1,2. Comorbidity analysis was restricted to primary operations performed prior to the end 
of November 2012 as HES records beyond this date were not available. BMI was analysed separately as data 
were incomplete and not recorded in the early phase of NJR. Variable coding and frequency counts are shown in 
Supplementary Material Tables S1 and S2.
Statistical Methods. Two complementary approaches were adopted (i) an internal and (ii) an external com-
parison. The internal comparison used proportional hazards regression models to model the time to death from 
any cause in the presence of censoring (see Supplementary Material Text S1). To capture changing hazard ratios 
over time, we used flexible parametric survival modelling (FPM)11,12 implemented in Stata13,14. We first sought 
parsimonious models with just gender and (continuous) age at operation (as four restricted cubic splines)12. 
We assessed time-varying effects of gender and age by adding appropriate terms to the model to represent these 
effects, assessing the changes with likelihood ratio tests and examination of Akaike and Bayesian information 
criteria (AIC and BIC respectively), giving preference to the former. We then added other risk-factor variables 
to the model, using a series of 0/1 indicators for each (Supplementary Material Tables S1 and S2). The effects of 
each risk factor on the HRs were assessed, adjusting for age and gender, and whether their effects changed with 
time. A final multivariable model was constructed of all surgical risk factors, plus age, gender, ASA and year of 
surgery. Adjusted HRs for each risk factor were plotted. Further models additionally adjusted for comorbidity and 
quintiles of area deprivation.
The external comparison compared the observed mortality patterns for exposures in relation to expected mor-
tality using national rates. In contrast to the internal comparison, above, this analysis looked at one risk factor at a 
time, conditioning on contemporaneous age group and sex. To test for differing patterns of mortality over time we 
calculated Standardised Mortality Ratios (SMRs) by time interval (0–90 days, 90 days–1 year, 3–5 years, 5–7 years 
and 7 years+) from the primary operation by dividing the observed numbers of deaths (O) in each of these inter-
vals by the expected numbers (E). The latter were calculated from ONS age/sex mid-year populations15 and rele-
vant deaths16 for England and Wales. We did this with respect to (i) all cause deaths (ii) respiratory system deaths 
(all ICD-10 ‘J’ codes) and (iii) deaths from cancers that were believed to be related to smoking (see Supplementary 
Material Text S2). We also explored cardiovascular deaths, but these results are not shown for simplicity. These 
cause-specific analyses could only be performed for the subsets of patients with associated HES records (332,724 
hips; 384,291 knees). We plotted the temporal changes in (logged) SMR with time (see Supplementary Material 
Fig. S1), exploring the observed patterns with Poisson regression models, with the expected number of deaths as 
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the offsets. Excluding the 90-day period deaths post operation, the remaining intervals were coded: 90-days to 1 
year = 0, 1–3 years = 1, 3 to 5 years = 2, 5 to 7 years = 3, 7 years plus = 4. The effects of the risk factor was assessed 
by fitting a group effect allowing for a common slope. Temporal divergence/convergence was tested by including 
a group by time period interaction. We hypothesised that if there were or were not group differences due to differ-
ent intercepts but we observed the same slope, this would be suggestive of a causal effect. If there was a difference 
in the slopes, regardless of whether there was a difference or not in the intercept, this would represent a selection 
effect and be most likely observed as an improved SMR in the early period which abated with time as the benefit 
of the selection effect was reduced.
Consent. Patients consent to participate was obtained at the point of data capture by the NJR. As this was an 
analysis of anonymised routinely collected, no separate ethical approval was required.
Results
In modelling the baseline hazard for the internal model, 4 and 3 ‘knots’ (i.e. degrees of freedom (df) = 5 and 4) 
sufficiently captured the hip and knee patterns seen in our earlier analyses1,2; i.e. short term increases that sub-
sided by 90 and 45-days, respectively, thereafter increasing with time, reflecting normal mortality.
The effects of both age and gender on the hazard rate were time-varying; Supplementary Material Fig. S2 
details how they were modelled, the magnitude of their effects and illustrates that the estimated cumulative mor-
tality fitted the observed mortality well. Supplementary Material Fig. S3 details the results from adding the other 
surgical covariates. Supplementary Material Figs S4 and S5 document additional analyses including bearing sur-
face and grouped BMI.
Posterior approach. The internal comparison for all-cause mortality showed a significant time-varying 
effect of the posterior approach compared with ‘other’ approaches (p < 0.001, likelihood ratio test); there was 
an attenuation of the protective hazard ratio by 2 years (Fig. 1). The external comparison for all-cause mortality 
found a group difference, the biggest difference was in the earliest period after which the SMRs were fairly similar 
for both groups, but slightly lower for the posterior approach (Table 1). There was no evidence of selection as 
smoking-related cancer mortality was almost identical across the exposure groups but far less than expected due 
to the population being selected for an elective operation. Respiratory mortality was less in the posterior approach 
group (p = 0.05).
Mechanical thromboprophylaxis. Internal modelling showed a relative decrease in risk of death initially 
when mechanical thromboprophylaxis was used, this effect diminished with time (p = 0.01) over a long period, 
which was more suggestive of selection rather than causal effect (Fig. 2a). The external comparison found evi-
dence of a group effect for mechanical thromboprophylaxis (p < 0.001); this was most marked in the perioper-
ative period but those that received it had lower mortality at all time periods, though the time interaction was 
consistent with chance. There was a weak suggestion that those that received it had lower smoking-related mor-
tality, which was more marked for respiratory system mortality (p = 0.07) (Table 2).
Chemical thromboprophylaxis. In the internal comparison, compared with a referent group of ‘no chem-
oprophylaxis’ (red), ‘aspirin only’ (black) was associated with a reduction in mortality that persisted (Fig. 2b). 
‘Heparin + aspirin’ (brown dashed), was associated with an initial marked reduction that slowly receded; ‘Heparin 
only’ (blue), was associated with a less marked reduction that also slowly receded; a similar but again less marked 
effect was seem with ‘other chemoprophylaxis/other combinations’ (green).
Figure 1. Hazard rates ratios (with pointwise 95% CIs) associated with a posterior approach for hips (adjusting 
for time varying effects of age, gender, year of operation, ASA, mechanical and chemical thromboprophylaxis, 
anaesthetic used and implant type).
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For the external comparison, chemical thromboprophylaxis was grouped into aspirin alone, other combina-
tions and none. The external comparison showed slightly different results, both aspirin and other combinations 
had lower 90-day mortality compared to none but after this period, all-cause mortality was slightly lower for 
aspirin (group effect p = 0.009) than those with none, with no evidence of a time interaction (Table 3). Similarly, 
there was little difference in smoking related cancer mortality for any of the groups suggesting little or no selec-
tion. Interestingly, there was a persistent reduction in circulatory disease deaths as aspirin had a lower SMR for 
all time periods than no aspirin (data not shown; group difference p = 0.007) which would be consistent with a 
longer term cardioprotective effect.
HIP PRIMARIES
Main cause of death (ICD10)
(i) All causes of death (ii) Respiratory system (all ‘J’ codes) (iii) ‘Cancers related to smoking’*
Posterior (n = 218,566)
Other approaches 
(n = 205,590) Posterior (n = 168,674)
Other approaches 
(n = 164,060) Posterior (n = 168,674)
Other approaches 
(n = 164,060)
O/E O/E O/E O/E O/E O/E
All deaths 13,931/24,662.3 = 0.56 [0.56–0.57]
19,828/32,457.6 = 0.61 
[0.60–0.62]
1,129/2,751.0 = 0.41 
[0.39–0.44]
1,799/3,806.1 = 0.47 
[0.45–0.50]
2,012/2,721.7 = 0.74 
[0.71–0.77]
2,618/3,530.9 = 0.74 
[0.71–0.77]
Deaths by time interval post primary:
Within 90 d 798/1,380.0 = 0.58 [0.54–0.62]
1,053/1,504.7 = 0.70 
[0.66–0.74]
50/154.6 = 0.32 
[0.24–0.43]
72/173.8 = 0.41 
[0.32–0.52]
37/170.9 = 0.22 
[0.15–0.30]
34/183.8 = 0.18 
[0.13–0.26]
90 d to 1 y 1,585/4,023.5 = 0.39 [0.37–0.41]
1,906/4,500.8 = 0.42 
[0.40–0.44]
103/452.9 = 0.23 
[0.19–0.28]
145/524.0 0.28 
[0.23–0.33]
263/489.5 = 0.54 
[0.47–0.61]
299/540.9 = 0.55 
[0.49–0.62]
1 y to 3 y 4,557/9,025.6 = 0.50 [0.49–0.52]
5,652/10,877.6 = 0.52 
[0.51–0.53]
343/1,016.8 = 0.34 
[0.30–0.37]
464/1,279.0 = 0.36 
[0.33–0.40]
776/1,029.6 = 0.75 
[0.70–0.81]
867/1,236.2 = 0.70 
[0.66–0.75]
3 y to 5 y 3,884/6,110.2 = 0.64 [0.62–0.66]
5,646/8,404.2 = 0.67 
[0.65–0.69]
358/680.0 = 0.53 
[0.47–0.58]
537/987.8 = 0.54 
[0.50–0.59]
555/638.7 = 0.87 
[0.80–0.94]
795/881.3 = 0.90 
[0.84–0.97]
5 y to 7 y 2,258/3,110.2 = 0.73 [0.70–0.76]
3,786/5,078.3 = 0.75 
[0.72–0.77]
195/336.7 = 0.58 
[0.50–0.67]
385/593.5 = 0.65 
[0.59–0.72]
296/299.7 = 0.99 
[0.88–1.11]
443/494.7 = 0.90 
[0.81–0.98]
7 y+ 849/1,012.8 = 0.84 [0.78–0.90]
1,785/2,092.0 = 0.85 
[0.81–0.89]
80/110.0 = 0.73 
[0.58–0.91]
196/248.1 = 0.79 
[0.68–0.91]
85/93.2 = 0.91 
[0.73–1.13]
180/194.0 = 0.93 
[0.80–1.07]
Post 90-day 
modelling: Group x 
period interaction; 
Group difference**
Posterior vs. other: P = 0.195; P = 0.001 Posterior vs. other: P = 0.548; P = 0.045 Posterior vs. other: P = 0.550; P = 0.340
Table 1. Comparison of SMRs between posterior approach and other surgical approaches for hips. (Ratios 
of observed (O) to expected (E) numbers of deaths obtained from national rates [with 95% CI shown in 
parentheses]). *See text for details; **Assessed in the absence of a significant group x period interaction (but 
assuming a common slope).
Figure 2. (a) and (b) Hazard rates ratios (with pointwise 95% CIs) associated with (a) mechanical and (b) 
chemical thromboprophylaxis for hips (adjusting for time varying effects of age, gender, year of operation, ASA, 
surgical approach, anaesthetic used and implant type).
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Type of anaesthesia. The internal comparison found that compared with general anaesthetic (GA), spinal 
anaesthetic was more advantageous early on but this effect diminished with time, whilst spinal plus GA seemed to 
show persistent reduced mortality (Fig. 3). For the external comparison, anaesthesia was grouped into spinal only, 
GA only, spinal plus GA and other combinations. The most marked difference was for spinal plus GA versus GA 
where the former group had lower mortality at all time points (Table 4). This was also seen for smoking related 
cancers and there was evidence of a group by time interaction (p = 0.03) consistent with selection. Spinal alone 
compared to GA was more suggestive of a causal effect as the mortality benefits were only seen in the perioper-
ative period and there was no suggestion of reduced smoking-related cancer mortality. Respiratory deaths were, 
if anything, higher in this group compared to the GA group suggesting that there may be more, rather than less, 
comorbidity.
Type of hip prosthesis. The internal modelling found that the resurfacing hazard ratios remained lower 
than the cemented referent group over time (Fig. 4). A similar time-invariant pattern was seen with unce-
mented hips. In the external comparison, resurfacing was associated with reduced all cause (p-value for inter-
action = 0.01) and smoking-related cancer mortality that was seen over the follow-up period consistent with a 
selection effect (Table 5).
Supplementary Material Fig. S4 shows results from the internal model which take into account bearing sur-
face. Supplementary Material Fig. S5 shows results for grouped BMI.
Type of knee prosthesis. The internal comparison showed a survival benefit with the use of unicondy-
lar knee replacements that waned over time (Fig. 5). The external comparison found a group effect (p < 0.001) 
though all-cause mortality was reduced across all the time periods and was not restricted to the early period. 
There was no evidence of reduced smoking-related cancers but respiratory deaths were reduced in the interven-
tion group (SMR 0.30, 95% CI 0.24, 0.36 versus 0.38, 95% CI 0.36, 0.39, p = 0.01) (Table 6).
Discussion
We have used the extended mortality follow-up from the NJR to explore where some of the previously reported 
“protective” surgical-related exposures are truly causally related or the result of confounding. The reduced mor-
tality seen for patients undergoing joint replacement was markedly attenuated, though not totally abolished, over 
time, highlighting a healthy selection effect, a finding consistent with previous studies17–21.
Of seven interventions studied, we believe three interventions (hip resurfacing, combined spinal and gen-
eral anaesthetic, unicondylar knee implants) showed patterns more consistent with confounding by indication; 
healthier patients being more likely to have received the intervention. The evidence for this seemed strongest for 
hip resurfacing where patients showed persistent reduced mortality from all cause and smoking-related cancers. 
This type of hip replacement has specifically been marketed for the more active patient, reflected in the demo-
graphics observed6. Possibly earlier/better mobilisation might contribute to the decreased mortality22, however, 
HIP PRIMARIES
Main cause of death (ICD10)
(i) All causes of death (ii) Respiratory system (all ‘J’ codes) (iii) ‘Cancers related to smoking’*
Yes (n = 366,820) No** (n = 56,157) Yes (n = 285,305) No*** (n = 46,468) Yes (n = 285,305) No*** (n = 46,468)
O/E O/E O/E O/E O/E O/E
All deaths 26,939/46,694.3 = 0.58 [0.57–0.58]
6,566/10,038.2 = 0.65 
[0.64–0.67]
2,287/5,301.2 = 0.43 
[0.41–0.45]
615/1,210.2 = 0.51 
[0.47–0.55]
3,701/5,062.2 = 0.73 
[0.71–0.76]
898/1,148.0 = 0.78 
[0.73–0.84]
Deaths by time interval post primary:
Within 90 d 1,542/2,493.0 = 0.62 [0.59–0.65]
304/383.0 = 0.79 
[0.71–0.89]
105/282.3 = 0.37 
[0.30–0.45]
17/45.1 = 0.38 
[0.22–0.60]
65/304.6 = 0.21 
[0.16–0.27]
6/49.1 = 0.12 
[0.04–0.27]
90 d to 1 y 2,939/7,320.3 = 0.40 [0.39–0.42]
545/1,177.0 = 0.46 
[0.42–0.50]
216/834.4 = 0.26 
[0.23–0.30]
31/139.6 = 0.22 
[0.15–0.32]
479/878.7 = 0.55 
[0.50–0.60]
82/148.4 = 0.55 
[0.44–0.69]
1 y to 3 y 8,468/16,707.7 = 0.51 [0.50–0.52]
1,705/3,117.1 = 0.55 
[0.52–0.57]
677/1,911.4 = 0.35 
[0.33–0.38]
128/375.4 = 0.34 
[0.28–0.41]
1,367/1,883.0 = 0.73 
[0.69–0.77]
269/373.8 = 0.72 
[0.64–0.81]
3 y to 5 y 7,587/11,683.6 = 0.65 [0.63–0.66]
1,896/2,745.9 = 0.69 
[0.66–0.72]
686/1,326.6 = 0.52 
[0.48–0.56]
204/331.2 = 0.62 
[0.53–0.71]
1,061/1,204.0 = 0.88 
[0.83–0.94]
285/306.7 = 0.93 
[0.82–1.04]
5 y to 7 y 4,597/6,291.2 = 0.73 [0.71–0.75]
1,385/1,808.8 = 0.77 
[0.73–0.81]
415/701.4 = 0.59 
[0.54–0.65]
156/218.2 = 0.71 
[0.61–0.84]
543/595.7 = 0.91 
[0.84–0.99]
187/189.3 = 0.99 
[0.85–1.14]
7 y+ 1,806/2,198.4 = 0.82 [0.78–0.86]
732/806.2 = 0.91 
[0.84–0.98]
188/245.1 = 0.77 
[0.66–0.89]
79/100.6 = 0.78 
[0.62–0.98]
186/196.1 = 0.95 
[0.82–1.09]
69/80.8 = 0.85 
[0.66–1.08]
Post 90-day modelling: 
Group x period 
interaction; Group 
difference****
Yes vs. No: P = 0.255; P < 0.001 Yes vs. No: P = 0.352; P = 0.069 Yes vs. No: P = 0.650; P = 0.585
Table 2. Comparison of SMRs between those given or not given any mechanical thromboprophylaxis (i.e. 
‘Yes’ vs. ‘No’) for hips. (Ratios of observed (O) to expected (E) numbers of deaths obtained from national rates 
[with 95% CI shown in parentheses]). *See text for details. **Excludes 1,179 cases where thromboprophylaxis 
was missing. ***Excludes 961 cases where thromboprophylaxis was missing. ****Assessed in the absence of a 
significant group x period interaction (but assuming a common slope).
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this is unlikely to explain the observed difference in smoking-related deaths. The results for the combined spinal 
and GA anaesthesia group were similar, the patients had better all-cause mortality and a time interaction for 
smoking–related cancers. Similar results were seen for unicondylar knee replacement; although there no differ-
ence for smoking-related cancers, the reduction in respiratory deaths suggested a selection effect.
HIP 
PRIMARIES
Main cause of death (ICD10)
(i) All causes of death (ii) Respiratory system (all ‘J’ codes) (iii) ‘Cancers related to smoking’*
Aspirin only 
(n = 47,739)
Others/other 
combinations 
(n = 328,580)
None** 
(n = 46,658)
Aspirin only 
(n = 34,297)
Others/other 
combinations 
(n = 265,258)
None*** 
(n = 32,218)
Aspirin only 
(n = 34,297)
Others/other 
combinations 
(n = 265,258)
None*** 
(n = 32,218)
O/E O/E O/E O/E O/E O/E O/E O/E O/E
All deaths 4,871/8,241.2 =  0.59 [0.57–0.61]
23,273/39,932.4 = 
0.58 [0.58–0.59]
5,361/8,558.8 =  
0.63 [0.61–0.64]
443/901.6 =  
0.49 [0.45–0.54]
2,009/4,720.3 =  
0.43 [0.41–0.44]
450/889.4 =  
0.51 [0.46–0.55]
645/846.4 =  
0.76 [0.70–0.82]
3,305/4,535.4 =  
0.73 [0.70–0.75]
649/828.4 =  
0.78 [0.72–0.85]
Deaths by time interval post primary:
Within 90d 218/323.7 =  0.67 [0.59–0.77]
1,380/2,226.9 =  
0.62 [0.59–0.65]
248/325.4 =  
0.76 [0.67–0.86]
19/34.2 =  0.56 
[0.33–0.87]
87/260.6 =  0.33 
[0.27–0.41]
16/32.6 =  0.49 
[0.28–0.80]
9/36.8 =  0.24 
[0.11–0.46]
50/282.4 =  0.18 
[0.13–0.23]
12/34.5 =  0.35 
[0.18–0.61]
90 d to 1 y 411/998.1 =  0.41 [0.37–0.45]
2,648/6,491.9 =  
0.41 [0.39–0.42]
425/1,007.4 =  
0.42 [0.38–0.46]
29/106.2 =  0.27 
[0.18–0.39]
190/766.0 =  
0.25 [0.21–0.29]
28/101.8 =  0.28 
[0.18–0.40]
68/111.7 =  0.61 
[0.47–0.77]
438/809.9 =  
0.54 [0.49–0.59]
55/105.5 =  0.52 
[0.39–0.68]
1 y to 3 y 1,342/2,641.6 =  0.51 [0.48–0.54]
7,423/14,480.18 = 
0.51 [0.50–0.52]
1,408/2,703.1 =  
0.52 [0.49–0.55]
108/287.0 =  
0.38 [0.31–0.45]
605/1,722.1 =  
0.35 [0.32–0.38]
92/277.7 =  0.33 
[0.27–0.41]
206/283.3 =  
0.73 [0.63–0.83]
1,232/1,703.7 =  
0.72 [0.68–0.76]
198/269.8 =  
0.73 [0.64–0.84]
3 y to 5 y 1,377/2,245.2 =  0.61 [0.58–0.65]
6,498/9,800.9 =  
0.66 [0.65–0.68]
1,607/2,383.4 =  
0.67 [0.64–0.71]
139/247.2 =  
0.56 [0.47–0.66]
601/1,160.7 =  
0.52 [0.48–0.56]
150/250.0 =  
0.60 [0.51–0.70]
195/225.7 =  
0.86 [0.75–0.99]
937/1,058.1 =  
0.89 [0.83–0.94]
214/226.8 =  
0.94 [0.82–1.08]
5 y to 7 y 1,048/1,445.7 =  0.72 [0.68–0.77]
3,780/5,105.0 =  
0.74 [0.72–0.76]
1,154/1,549.3 =  
0.74 [0.70–0.79]
94/160.3 =  0.59 
[0.47–0.72]
373/595.6 =  
0.63 [0.56–0.69]
104/163.8 =  
0.63 [0.52–0.77]
127/136.1 =  
0.93 [0.78–1.11]
480/508.9 =  
0.94 [0.86–1.03]
123/140.0 =  
0.88 [0.73–1.05]
7 y+ 475/587.0 =  0.81 [0.74–0.89]
1,544/1,827.4 =  
0.84 [0.80–0.89]
519/590.3 =  
0.88 [0.81–0.96]
54/66.7 =  0.81 
[0.61–1.06]
153/215.4 =  
0.71 [0.60–0.83]
60/63.6 =  0.94 
[0.72–1.22]
40/52.7 =  0.76 
[0.54–1.03]
168/172.4 =  
0.97 [0.83–1.13]
47/51.8 =  0.91 
[0.67–1.21]
Post 90-day 
modelling: 
Group x 
period 
interaction; 
Group 
diff.****
Aspirin vs None: 
P = 0.569; P = 0.009
Other vs None: P = 0.561; 
P = 0.241
Aspirin vs None: 
P = 0.290; P = 0.637
Other vs None: P = 0.459; 
P = 0.136
Aspirin vs None:  
P = 0.513; 
P = 0.748
Other vs None: P = 0.384; 
P = 0.948
Table 3. Comparison of SMRs between subgroups of chemical thromboprophylaxis for hips (‘aspirin only’, 
‘others/other combinations’ (see table footnote) and ‘none’). (Ratios of observed (O) to expected (E) numbers 
of deaths obtained from national rates [with 95% CI shown in parentheses]). *See text for details. **Excludes 
1,179 cases where thromboprophylaxis was missing. ***Excludes 961 cases where thromboprophylaxis 
was missing. ****Group difference assessed in the absence of a significant group x period interaction (but 
assuming a common slope); ‘Others/other combinations’ here includes Heparin, Heparin + aspirin plus other 
thromboprophylaxis agents plus any combinations of these, either with each other or with aspirin and/or 
Heparin.
Figure 3. Hazard rates ratios associated with anaesthetic for hips (adjusting for time varying effects of age, 
gender, year of operation, ASA, surgical approach, mechanical prophylaxis, chemical prophylaxis and implant 
type). The referent group is ‘GA only’ (red line); other groups are as shown in the legend but 95% CIs have been 
omitted for simplification.
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Mechanical thromboprophylaxis was less consistent with an apparent genuine intervention-related reduction. 
There was little evidence that those receiving intervention were otherwise healthier and the internal comparison 
found a slow waning effect of the mortality risk over time, so we remain unsure. Chemoprophylaxis with aspi-
rin was interesting as aspirin was associated with a reduction in all-cause mortality which was sustained over 
time and this was mirrored in fewer circulatory disease deaths. We have assumed that any causal perioperative 
intervention would only exert its effect in the early postoperative period. However, it is possible that previously 
untreated patients with heart disease who are given aspirin perioperatively keep taking it, leading to decreased 
risk of mortality from cardiac events23,24. The mortality patterns for a posterior approach were ambiguous, sug-
gesting a selection effect but also possibly a causal benefit with only short-term mortality gains. There was no 
evidence of lower smoking related mortality but weak evidence of reduced respiratory deaths in the posterior 
approach group. This may be because the posterior approach was associated with less bleeding, tissue damage25 
and better early mobilisation26, hence reduced risk of complications such as thrombosis and therefore a reduction 
in early deaths. In the longer term, preservation of the abductor muscles in the posterior group compared to the 
most common alternative (lateral/anterolateral approach) may lead to improved mobility27 and a slow attenua-
tion and protection from respiratory deaths. There is unlikely to be a selection effect as the vast majority of hip 
replacements are performed by surgeons who use either the posterior or lateral/anterolateral approach with no 
patient level selection. Some selection is observed amongst surgeons who perform minimally invasive or ante-
rior approaches for patients with lower body mass index but such procedures account for only 4% of the cases 
recorded by the NJR28. Most convincing were the results for those receiving spinal anaesthetic. Here only peri-
operative mortality was reduced and if anything, respiratory mortality was higher in the spinal group suggesting 
HIP PRIMARIES
‘Main’ cause of death (ICD10)
(i) All causes of death (ii) Respiratory system (all ‘J’ codes)
Spinal only 
(n = 177,112)
GA only 
(n = 100,218)
Spinal + GA only 
(n = 51,747)
Others/Other 
combinations** 
(n = 83,461)
Spinal only 
(n = 143,511) GA only (n = 73,636)
Spinal + GA 
only 
(n = 39,409)
Others/Other 
combinations*** 
(n = 66,322)
O/E O/E O/E O/E O/E O/E O/E O/E
All deaths 13,035/22,272.3 = 0.59 [0.58–0.60]
7,763/13,029.4 = 0.60 
[0.58–0.61]
3,457/6,562.5 = 0.53 
[0.51–0.54]
7,945/12,851.3 = 0.62 
[0.60–0.63]
1,197/2,635.0 = 0.45 
[0.43–0.48] 560/1,393.8 = 0.40 [0.37–0.44]
242/709.9 = 0.34 
[0.30–0.39]
771/1,522.4 = 0.51 
[0.47–0.54]
Deaths by time interval post primary:
Within 90 d 772/1,242.9 = 0.62 [0.58–0.67]
445/642.1 = 0.69 
[0.63–0.76]
178/338.9 = 0.53 
[0.45–0.61]
398/575.2 = 0.69 
[0.63–0.76]
49/146.5 = 0.33 
[0.25–0.44]
27/68.2 = 0.40 
[0.26–0.58] 9/36.8 = 0.24 [0.11–0.46]
30/66.6 = 0.45 
[0.30–0.64]
90 d to 1 y 1,458/3,621.1 = 0.40 [0.38–0.42]
758/1,899.6 = 0.40 
[0.37–0.43]
375/999.6 = 0.38 
[0.34–0.42]
784/1,734.7 = 0.45 
[0.42–0.48]
103/429.8 = 0.24 
[0.20–0.29]
47/203.1 = 0.23 
[0.17–0.31] 18/109.3 = 0.16 [0.10–0.26]
63/202.1 = 0.31 
[0.24–0.40]
1 y to 3 y 4,087/8,079.9 = 0.51 [0.49–0.52]
2,335/4,488.2 = 0.52 
[0.50–0.54]
1,062/2,292.0 = 0.46 
[0.44–0.69]
2,316/4,282.2 = 0.54 
[0.52–0.56]
363/962.5 = 0.38 
[0.34–0.42]
141/484.0 = 0.29 
[0.25–0.34] 71/250.4 = 0.28 [0.22–0.36]
181/505.0 = 0.36 
[0.31–0.41]
3 y to 5 y 3,703/5,487.6 = 0.67 [0.65–0.70]
2,113/3,253.4 = 0.65 
[0.62–0.68]
950/1,628.8 = 0.58 
[0.55–0.62]
2,234/3,398.4 = 0.66 
[0.63–0.69]
382/647.0 = 0.59 
[0.53–0.65]
165/348.4 = 0.47 
[0.40–0.55] 67/174.7 = 0.38 [0.30–0.49]
232/404.9 = 0.57 
[0.50–0.65]
5 y to 7 y 2,161/2,885.0 = 0.75 [0.72–0.78]
1,420/1,908.1 = 0.74 
[0.71–0.78]
605/929.6 = 0.65 
[0.60–0.70]
1,520/2,030.2 = 0.75 
[0.71–0.79]
207/334.7 = 0.62 
[0.54–0.71]
113/201.0 = 0.56 
[0.46–0.68] 50/98.9 = 0.51 [0.38–0.67]
179/242.2 = 0.74 
[0.63–0.86]
7 y+ 854/955.8 = 0.89 [0.83–0.96]
692/837.9 = 0.83 
[0.77–0.89]
287/373.5 = 0.77 
[0.68–0.86]
693/830.5 = 0.83 
[0.77–0.90]
93/114.4 = 0.81 
[0.66–1.00]
57/89.2 = 0.64 
[0.48–0.83] 27/39.9 = 0.68 [0.45–0.98]
86/101.6 = 0.85 
[0.68–1.05]
Post 90-day 
modelling: 
Group x period 
interaction; Group 
difference ****
Spinal vs. GA: P = 0.071; P = 0.386 Spinal + GA vs. GA: P = 0.874; P < 0.001 Spinal vs. GA: P = 0.615; P < 0.001 Spinal + GA vs. GA: P = 0.417; P = 0.081
HIP PRIMARIES
‘Main’ cause of death (ICD10)
(iii) ‘Cancers related to smoking’*
Spinal only (n = 143,511) GA only (n = 73,636) Spinal + GA only (n = 39,409)
Others/Other combinations*** 
(n = 66,322)
O/E O/E O/E O/E
All deaths 1,881/2,507.1 = 0.75 [0.72–0.78] 1,010/1,353.3 = 0.75 [0.70–0.79] 467/684.0 = 0.68 [0.62–0.75] 1,048/1,434.4 = 0.73 [0.69–0.78]
Deaths by time interval post primary:
With in 90 d 29/157.5 = 0.18 [0.12–0.26] 17/75.1 = 0.23 [0.13–0.36] 10/40.3 = 0.25 [0.12–0.46] 13/71.2 = 0.18 [0.10–0.31]
90 d to 1 y 259/450.5 = 0.57 [0.51–0.65] 106/218.3 = 0.49 [0.40–0.59] 65/116.9 = 0.56 [0.43–0.71] 118/211.6 = 0.56 [0.46–0.67]
1 y to 3 y 679/944.3 = 0.72 [0.67–0.78] 356/486.1 = 0.73 [0.66–0.81] 172/249.3 = 0.69 [0.59–0.80] 358/495.9 = 0.72 [0.65–0.80]
3 y to 5 y 548/584.8 = 0.94 [0.86–1.02] 280/324.2 = 0.86 [0.77–0.97] 141/159.9 = 0.88 [0.74–1.04] 303/367.2 = 0.83 [0.73–0.92]
5 y to 7 y 275/280.6 = 0.98 [0.87–1.10] 180/176.3 = 1.02 [0.88–1.18] 55/85.1 = 0.65 [0.49–0.84] 184/206.8 = 0.89 [0.77–1.03]
7 y+ 91/89.4 = 1.02 [0.82–1.25] 71/73.4 = 0.97 [0.76–1.22] 24/32.5 = 0.74 [0.47–1.10] 72/81.5 = 0.88 [0.69–1.11]
Post 90-day 
modelling: 
Group x period 
interaction; Group 
difference ****
Spinal vs. GA: P = 0.806; P = 0.350 Spinal + GA vs. GA: P = 0.034; N/A
Table 4. Comparison of SMRs between specific anaesthetic groups for hips (‘Spinal only’, ‘GA only’, ‘Spinal + GA 
only’ and ‘others/other combination’ (see table footnote). (Ratios of observed (O) to expected (E) numbers of 
deaths obtained from national rates [with 95% CI shown in parentheses]). *See text for details. **Excludes 11,618 
cases where anaesthetic was missing. ***Excludes 9,856 cases where anaesthetic was missing. ****Assessed in the 
absence of a significant group x period interaction (but assuming a common slope).
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that patients with worse lung function may have been selected for this type of anaesthesia. Spinal anaesthesia has 
been demonstrated to be associated with lower risk of complications such as surgical site infection, pulmonary 
complication, blood transfusion, thromboembolic events, prolonged length of stay and intensive care unit admis-
sion when compared to general anaesthesia29. Avoidance of these complications may therefore reduce the risk of 
mortality. Smaller evidence synthesis studies have only demonstrated a reduced length of stay in spinal compared 
to general anaesthesia30 but this may reflect the small overall sample size and the need for follow up beyond hos-
pital discharge to assess the effect of the type of anaesthesia on mortality; as recommended by Johnson et al.30, our 
analysis includes consideration of intermediate and long-term outcome.
The NJR is the largest joint replacement register in the world6. Linkage with other comprehensive national 
databases allows good data coverage but the data are observational and causality cannot usually be proven. 
However, we feel that triangulating findings across different analytical strategies points more strongly to causation 
and may be an analytical strategy for trying to infer causality with other large sets of observational data when it is 
not feasible to undertake randomised controlled trials.
Figure 4. Hazard rates ratios associated with hip implant type (adjusting for time varying effects of age, gender, 
year of operation, ASA, surgical approach, anaesthetic used, mechanical prophylaxis and chemical prophylaxis).
HIP PRIMARIES
Main cause of death (ICD10)
(i) All causes of death (ii) Respiratory system (all ‘J’ codes) (iii) ‘Cancers related to smoking’*
Resurfacings 
(n = 27,921)
Uncemented 
(n = 158,874)
Other hip types** 
(n = 237,330)
Resurfacings 
(n = 17,557)
Uncemented 
(n = 124,338)
Other hip types*** 
(n = 190,816)
Resurfacings 
(n = 17,557)
Uncemented 
(n = 124,338)
Other hip types*** 
(n = 190,816)
O/E O/E O/E O/E O/E O/E O/E O/E O/E
All deaths 569/1,277.6 = 0.45 [0.41–0.48]
7823/13,591.3 = 0.58 
[0.56–0.59]
25,361/42,241.3 = 0.60 
[0.59–0.61]
12/73.2 = 0.16 
[0.08–0.29]
636/1,466.0 = 0.43 
[0.40–0.47]
2,280/5,016.9 = 0.45 
[0.44–0.47]
87/178.7 = 0.49 
[0.39–0.60]
1,265/1,725.1 = 0.73 
[0.69–0.77]
3,276/4,347.9 = 0.75 
[0.73–0.78]
Deaths by time interval post primary:
Within 90 d 26/46.6 = 0.56 [0.36–0.82]
462/789.5 = 0.59 
[0.53–0.64]
1,361/2,048.5 = 0.67 
[0.63–0.70]
0/2.3 = 0.0 
[0.0–1.59]
29/83.1 0.35 
[0.23–0.50]
93/242.9 = 0.38 
[0.31–0.47]
1/6.3 = 0.16 
[0.00–0.89]
16/109.1 = 0.15 
[0.08–0.24]
54/239.3 = 0.23 
[0.17–0.29]
90 d to 1 y 45/146.1 = 0.31 [0.22–0.41]
963/2,313.8 = 0.42 
[0.38–0.44]
2,483/6,063.8 = 0.41 
[0.39–0.43]
0/7.4 = 0.0 
[0.0–0.50]
59/246.5 = 0.24 
[0.18–0.31]
189/723.0 = 0.26 
[0.23–0.30]
4/19.9 = 0.20 
[0.05–0.52]
180/315.8 = 0.57 
[0.49–0.66]
378/694.7 = 0.54 
[0.49–0.60]
1 y to 3 y 172/399.0 = 0.43 [0.37–0.50]
2,697/5,159.4 = 0.52 
[0.50–0.54]
7,338/14,342.8 = 0.51 
[0.50–0.52]
2/21.7 = 0.09 
[0.01–0.33]
213/558.1 = 0.38 
[0.33–0.44]
592/1,715.8 = 0.35 
[0.32–0.37]
23/55.8 = 0.41 
[0.26–0.62]
485/670.8 = 0.72 
[0.66–0.79]
1,134/1,539.0 = 0.75 
[0.69–0.78]
3 y to 5 y 169/361.0 = 0.47 [0.40–0.54]
2,176/3,291.1 = 0.66 
[0.63–0.69]
7,185/10,859.8 = 0.66 
[0.65–0.68]
7/21.4 = 0.33 
[0.13–0.67]
193/356.1 = 0.54 
[0.47–0.62]
695/1,290.0 = 0.54 
[0.50–0.58]
30/51.7 = 0.58 
[0.39–0.83]
342/399.0 = 0.86 
[0.77–0.95]
978/1,069.2 = 0.91 
[0.86–0.97]
5 y to 7 y 108/231.8 = 0.47 [0.38–0.56]
1,129/1,560.0 = 0.72 
[0.68–0.77]
4,805/6,394.3 = 0.75 
[0.73–0.77]
1/14.5 = 0.07 
[0.00–0.38]
104/168.6 = 0.62 
[0.50–0.75]
475/746.8 = 0.64 
[0.58–0.70]
20/32.9 = 0.61 
[0.37–0.94]
183/177.6 = 1.03 
[0.89–1.19]
535/583.7 = 0.92 
[0.84–1.00]
7y+ 49/93.1 = 0.53 [0.39–0.70]
396/477.6 = 0.83 
[0.75–0.92]
2,187/2,532.1 = 0.86 
[0.83–0.90]
2/5.8 = 0.34 
[0.04–1.24]
38/53.6 = 0.71 
[0.50–0.97]
236/298.4 = 0.79 
[0.69–0.90]
9/12.2 = 0.74 
[0.34–1.40]
59/52.7 = 1.12 
[0.85–1.44]
197/222.1 = 0.89 
[0.77–1.02]
Post 90-day 
modelling: 
Group x period 
Interaction; Group 
difference****
Resurfacing vs other: 
P = 0.012; N/A
Uncemented vs other: P = 0.328; 
P = 0.905
Resurfacing vs 
other: P = 0.911; 
P < 0.001
Uncemented vs other: P = 0.686; 
P = 0.764
Resurfacing vs 
other: P = 0.252; 
P < 0.001
Uncemented vs other: P = 0.140; 
P = 0.731
Table 5. Comparison of SMRs between hip resurfacings, uncemented total hip replacements and other types 
of hip implants (i.e. cemented, hybrid and reverse hybrid). (Ratios of observed (O) to expected (E) numbers of 
deaths obtained from national rates [with 95% CI shown in parentheses]). *See text for details. **Excludes 31 
where hip type was uncertain. ***Excludes 23 where hip type was uncertain. ****Assessed in the absence of a 
significant group x period interaction (but assuming a common slope).
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Data collection occurs at the point of surgical treatment and as such, variables that may change post oper-
atively, such as type of thromboprophylaxis cannot be reliably captured. Whilst the NJR does have a range of 
variables that attempt to adjust for case-mix/comorbidity, residual confounding always remains a possibility due 
to lack of good indicators of disease severity or early stage conditions, such as mild cognitive impairment or early 
dementia. Replication of our results in other national registries would be helpful especially if the patient selection 
factors differ from the UK, for example in predominantly private health care systems.
We present further data supporting the potential causal role for aspirin chemothromboprophylaxis, posterior 
approach and spinal anaesthetic in THR in decreasing post-operative mortality and we recommend that patients 
undergoing primary THR are treated with these modalities to reduce the risk of mortality. We believe that the 
apparent “protective” effect of hip resurfacing, spinal and GA, unicondylar knee replacement and mechanical 
thromboprophylaxis are more likely to be due to selection though the last two are more difficult to interpret and 
may have a combination of both selection and causal effects, requiring further investigation.
Figure 5. Hazard rates ratios for mortality after knee replacement associated with type of knee (adjusting for 
time varying effects of age, gender, year group and ASA; n = 469,952). The referent group ‘cemented’ is shown 
as a red line; solid black, brown, green and blue denote ‘uncemented, ‘hybrid’, ‘patellofemoral’ and ‘unicondylar’ 
respectively; 95% CIs shown as dashed lines in the same colours.
KNEE PRIMARIES
Main cause of death (ICD10)
(i) All causes of death (ii) Respiratory system (all ‘J’ codes) (iii) ‘Cancers related to smoking’*
Unicondylar only 
(n = 41,619)
All other knee types** 
(n = 428,333)
Unicondylar only 
(n = 30,661)
All other knee types*** 
(n = 353,600)
Unicondylar only 
(n = 30,661)
All other knee types*** 
(n = 353,600)
O/E O/E O/E O/E O/E O/E
All deaths 1,649/36,378.0 = 0.45 [0.43–0.48]
34,346/60,987.6 = 0.56 
[0.56–0.57]
108/364.7 = 0.30 
[0.24–0.36]
2,824/7,507.4 = 0.38 
[0.36–0.39]
281/469.8 = 0.60 
[0.53–0.67]
4,714/7,182.7 = 0.66 
[0.64–0.68]
Deaths by time interval post primary:
Within 90 d 45/174.0 = 0.26 [0.19–0.35]
1,676/3,044.8 = 0.55 
[0.52–0.58]
1/16.2 = 0.06 
[0.00–0.34]
110/362.8 = 0.30 
[0.25–0.37]
0/24.4 = 0.00 
[0.00–0.15]
38/405.6 = 0.09 
[0.07–0.13]
90 d to 1 y 131/522.7 = 0.25 [0.21–0.30]
3,228/9,042.5 = 0.36 
[0.34–0.37]
5/49.4 = 0.10 
[0.03–0.24]
194/1,088.5 = 0.18 
[0.15–0.21]
28/72.3 = 0.39 
[0.26–0.56]
478/1,182.4 = 0.40 
[0.37–0.44]
1 y to 3 y 490/1,247.7 = 0.39 [0.36–0.43]
10,465/21,273.7 = 0.49 
[0.48–0.50]
25/121.5 = 0.21 
[0.13–0.30]
755/2,602.3 = 0.29 
[0.27–0.31]
79/166.4 = 0.47 
[0.38–0.59]
1,792/2,614.7 = 0.69 
[0.65–0.72]
3 y to 5 y 502/941.8 = 0.53 [0.49–0.58]
9,845/15,614.8 = 0.63 
[0.62–0.64]
34/96.7 = 0.35 
[0.24–0.49]
872/1,936.4 = 0.45 
[0.42–0.48]
100/119.4 = 0.84 
[0.68–1.02]
1,388/1,756.5 = 0.79 
[0.75–0.83]
5 y to 7 y 347/544.3 = 0.64 [0.57–0.71]
6,431/8,734.7 = 0.74 
[0.72–0.75]
30/57.9 = 0.52 
[0.35–0.74]
593/1,091.0 = 0.54 
[0.50–0.59]
54/64.4 = 0.84 
[0.63–1.09]
760/902.3 = 0.84 
[0.78–0.90]
7 y+ 134/207.5 = 0.65 [0.54–0.76]
2,701/3,277.0 = 0.82 
[0.79–0.86]
13/22.9 = 0.57 
[0.30–0.97]
300/426.4 = 0.70 
[0.63–0.79]
20/22.9 = 0.87 
[0.53–1.35]
258/321.1 = 0.80 
[0.71–0.91]
Post 90-day 
modelling: Group x 
period interaction; 
Group difference ****
Unicondylar vs other: P = 0.203; P < 0.001 Unicondylar vs other: P = 0.329; P = 0.014 Unicondylar vs other: P = 0.110; P = 0.102
Table 6. Comparison of SMRs between unicondylar knees and other knee implant types. (Ratios of observed 
(O) to expected (E) numbers of deaths obtained from national rates [with 95% CI shown in parenthesis]). *See 
text for details. **Excludes 37 where knee type was uncertain. ***Excludes 30 where knee type was uncertain. 
****Assessed in the absence of a significant group x period interaction (but assuming a common slope).
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Data Availability
The data that support the findings of this study are available from the National Joint Registry but restrictions 
apply to the availability of these data, which were used under license for the current study, and so are not publicly 
available.
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